Genitourinary Cancer
Feature
Radiation Oncologists Fight for Payment Reform Amid Cuts
Over the past decade, radiation oncologists have seen a 23% drop in Medicare reimbursement for...
Feature
CMS Okays Payment for Novel AI Prostate Test
The test improves risk stratification or prognostication over standard clinical and pathologic tools, says expert.
From the Journals
SUDs rates highest in head, neck, and gastric cancer survivors
Alcohol use disorder was the most common type of SUD across multiple subtypes of cancer patients.
From the Journals
Side Effects of Local Treatment for Advanced Prostate Cancer May Linger for Years
A new study compared long-term side effects in men with advanced prostate cancer who received initial local treatment with those who opted for...
From the Journals
Optimal Follow-up After Fertility-Sparing Cervical Cancer Surgery
Investigators sought to find out if follow-up could be tailored to the patient’s risk for recurrence.
Latest News
Active Surveillance for Low-Risk PCa: Sprint or Marathon?
For some men, the strategy can prove to be short-lived, perhaps 5 years or less , or a life-long approach lasting until the man dies from another...
Latest News
ASCO details how to manage ongoing cancer drug shortage
“This guidance document aims to support clinicians, as they navigate the complexities of treatment planning amid the drug shortage.”
From the Journals
MRIs, MRI-guided biopsies detect prostate cancer affordably
There is “a growing consensus that the use of MRI and potential MRI-guided biopsy is cost effective.”
Latest News
Black men are at higher risk of prostate cancer at younger ages, lower PSA levels
A large Veterans Affairs study finds that Black men with a prebiopsy PSA level of 4.0 ng/mL had the same risk of prostate cancer as White men with...
Conference Coverage
Enfortumab vedotin/pembrolizumab hailed as new standard for upfront mUC
After decades of stagnation, an almost doubling of life expectancy has set a new bar for the first-line treatment of locally advanced/metastatic...
Conference Coverage
Enzalutamide improves metastasis-free survival, QoL in prostate cancer
“This is the first time we have seen this kind of results with a novel hormonal therapy without castration.”